- Home
- AQST vs AVR Comparison
AQST vs AVR Comparison
Compare AQST & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- AVR
- Stock Information
- Founded
- AQST 2004
- AVR 1999
- Country
- AQST United States
- AVR Australia
- Employees
- AQST N/A
- AVR N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- AVR
- Sector
- AQST Health Care
- AVR
- Exchange
- AQST Nasdaq
- AVR NYSE
- Market Cap
- AQST 272.9M
- AVR 241.5M
- IPO Year
- AQST 2018
- AVR 2024
- Fundamental
- Price
- AQST $2.71
- AVR $4.24
- Analyst Decision
- AQST Strong Buy
- AVR Strong Buy
- Analyst Count
- AQST 5
- AVR 4
- Target Price
- AQST $11.40
- AVR $16.50
- AVG Volume (30 Days)
- AQST 1.7M
- AVR 148.4K
- Earning Date
- AQST 05-12-2025
- AVR 05-13-2025
- Dividend Yield
- AQST N/A
- AVR N/A
- EPS Growth
- AQST N/A
- AVR N/A
- EPS
- AQST N/A
- AVR N/A
- Revenue
- AQST $54,228,000.00
- AVR $2,493,000.00
- Revenue This Year
- AQST N/A
- AVR $29.52
- Revenue Next Year
- AQST $40.62
- AVR $204.83
- P/E Ratio
- AQST N/A
- AVR N/A
- Revenue Growth
- AQST 5.29
- AVR N/A
- 52 Week Low
- AQST $2.12
- AVR $2.34
- 52 Week High
- AQST $5.80
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- AQST 54.01
- AVR N/A
- Support Level
- AQST $2.22
- AVR N/A
- Resistance Level
- AQST $2.79
- AVR N/A
- Average True Range (ATR)
- AQST 0.19
- AVR 0.00
- MACD
- AQST 0.04
- AVR 0.00
- Stochastic Oscillator
- AQST 75.64
- AVR 0.00
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.